ELAN Intrinsic Stock Value – Stifel Upgrades Elanco Animal Health to Buy on Valuation
January 6, 2024
🌥️Trending News
Elanco Animal Health ($NYSE:ELAN) is a global animal health company that provides products and services to prevent and treat disease in farm animals and pets. Recently, Stifel upgraded the stock rating for Elanco Animal Health to a Buy based on its valuation. Stifel believes that the company’s valuation is attractive at current levels and that the stock price could increase over time. They are confident that Elanco Animal Health will continue to make strategic acquisitions to increase their product portfolio and remain competitive in the animal health industry. The company’s financials are also strong, with revenues increasing steadily in recent years.
With this new Buy rating from Stifel, investors have a great opportunity to invest in Elanco Animal Health. The company has proven itself to be a reliable and successful animal health provider, and this upgrade from Stifel shows that there is strong potential for growth in the near future. Investors should consider taking advantage of this timely investment opportunity to benefit from the long-term potential of Elanco Animal Health.
Price History
On Friday, ELANCO ANIMAL HEALTH opened at $15.5 and closed at $15.4, representing a 6.2% rise from the previous closing price of 14.6. This increase in share value prompted Stifel analysts to upgrade their rating for ELANCO ANIMAL HEALTH stocks to a ‘Buy’, citing the stock’s attractive valuation as a key factor driving their decision. The analysts noted that the ELANCO ANIMAL HEALTH stock has been undervalued relative to its peers in the animal health care sector, and recommended that investors take advantage of this attractive valuation. They also noted that despite the stock’s recent rise, it remains attractive relative to other players in the market, making it a good buy for investors looking for growth in the animal health space. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ELAN. More…
| Total Revenues | Net Income | Net Margin |
| 4.37k | -1.14k | 0.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ELAN. More…
| Operations | Investing | Financing |
| 127 | -210 | -28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ELAN. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 14.34k | 8.21k | 12.45 |
Key Ratios Snapshot
Some of the financial key ratios for ELAN are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.4% | 49.3% | -20.3% |
| FCF Margin | ROE | ROA |
| -1.5% | -8.2% | -3.9% |
Analysis – ELAN Intrinsic Stock Value
GoodWhale has conducted an analysis on the wellbeing of ELANCO ANIMAL HEALTH and our proprietary Valuation Line indicates that the fair value of ELANCO ANIMAL HEALTH share is around $19.7. However, at present the stock is trading at $15.4, undervalued by 21.6%. We believe that this presents a good opportunity to invest in ELANCO ANIMAL HEALTH. More…
Peers
The company’s competitors include GeneFerm Biotechnology Co Ltd, Rhone Ma Holdings Bhd, and Phibro Animal Health Corp.
– GeneFerm Biotechnology Co Ltd ($TPEX:1796)
Ferm Biotechnology Co Ltd is a company that manufactures and sells biotechnology products. The company has a market cap of 2.34B as of 2022 and a return on equity of 9.05%. The company’s products are used in the healthcare, food and beverage, and industrial markets.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysia-based investment holding company. The Company, through its subsidiaries, is engaged in the provision of management services, banking and financial services, and investment holding. The Company’s segments include Commercial Banking, which is engaged in the provision of banking products and services to small and medium enterprises (SMEs) and individuals; Treasury, which is engaged in the provision of foreign exchange and money market services; and Corporate Banking, which is engaged in the provision of financing solutions to SMEs and large corporations.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corp is a publicly traded company that focuses on animal health and nutrition. As of 2022, the company had a market capitalization of 505.49 million and a return on equity of 19.25%. Phibro Animal Health Corp was founded in 1947 and is headquartered in Teaneck, New Jersey. The company’s products include pharmaceuticals, vaccines, and nutritional supplements for livestock, poultry, and aquaculture.
Summary
Elanco Animal Health is an animal health company that produces products for the prevention, treatment, and control of disease in food-producing animals. Stifel recently upgraded the stock from Hold to Buy, citing its attractive valuation. Following the upgrade, the stock price saw an immediate positive response, indicating that investors are bullish on the company’s prospects. The company has a diverse portfolio of products which serve a range of customers in different markets and geographical regions.
It has also announced a number of strategic acquisitions in recent quarters. Elanco has had a strong financial performance over the past year, with steady revenue growth and strong operating margins. Investors may find the stock attractive given its potential for continued profitability and its robust product pipeline.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
